Huang Guo, Deputy Director of the National Medical Products Administration, conducted research in Shanghai and other places to promote the digital transformation of the pharmaceutical industry.

Recently, Huang Guo, member of the Party Group and Deputy Director of the National Medical Products Administration, led a team to visit some pharmaceutical companies in Shanghai and Jiangsu to conduct research on artificial intelligence drug innovation, digital transformation of pharmaceutical production, and other related areas. Huang Guo emphasized that the National Medical Products Administration attaches great importance to digital empowerment, accelerating the development of new quality pharmaceutical productivity. It is necessary to continuously improve relevant policies, promote deep integration of scientific and technological innovation with pharmaceutical industry innovation, and support and encourage the use of AI in drug design at the R&D end, and establish intelligent production and quality control systems at the production end to enhance the level of informatization of the pharmaceutical industry chain. The Drug Center in the Yangtze River Delta region should play an important role in supporting the strategy of regional integration, improve the innovation service mechanism, strengthen cooperation with local regulatory departments, and serve the high-quality development of the pharmaceutical industry.